BNET Industries
Market Cap:$9.6M
Last Fiscal Year Sales:$456.6K
- Public
- US
Dow Jones Description
We are engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Our platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death (senescence) and for programmed cell death in humans (apoptosis). We are developing our technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. We are also researching applications of our technologies which may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma, and cardiovascular disease. One of the main advantages of our patent pending genetic technologies is their broad applicability. Our technology has shown the ability to enhance a wide variety of crops, which could be implemented by multiple licensing partners on a worldwide scale. We have already made progress to this end with our existing commercial relationships. Likewise, we are researching the feasibility of using our technologies as therapeutics in a variety of human health conditions and plan to establish a similar licensing network for pharmaceuticals. ...
Number of Employees 5
Contact Information
303 George St Ste 420
New Brunswick
(732) 296-8400
Peer Companies
NAICS Code : 541710
Recent Events
-
Senesco Technologies Reports First Quarter Fiscal 2010 Financial Results
-
Senesco Technologies, Inc. Announces Management Change
-
Certain Senesco Insiders to Purchase Senesco Securities Held by Stanford Venture Capital Holdings and by...
-
Senesco Technologies Reports Fiscal Year 2009 Financial Results
News & Analysis
Filter by
senesco technologies inc. - All News and Analysis
Senesco Technologies Closes on $1.5 Million of Previously Announced Financing
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX: SNT) today announced that on September 21, 2007 it has closed on $1.5 million of its previously announced private placement with YA Global Investments, LP ("YA Global") of an aggregate of up to $5 million, three-year secured convertible...
Amex Grants Extension for Senesco to Comply with Listing Requirements
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. (AMEX:SNT) (referred to herein as "Senesco" or the "Company") announced today that the Listings Qualifications Department (the "Exchange Staff") of the American Stock Exchange (the "Exchange") notified the Company that it accepted the Company's plan of compliance and granted the Company an extension...
Senesco Technologies Responds to AMEX Notice of Non Compliance
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. (the "Company") (AMEX:SNT) has submitted a plan advising the American Stock Exchange AMEX of action it has taken, or will take, which would bring the Company into compliance with the Exchange's continued listing standards. The Listings Qualifications Department of AMEX will evaluate...
Senesco Technologies Receives Notice of Non Compliance from AMEX
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. (the "Company") (AMEX:SNT) has received notice from The American Stock Exchange AMEX that AMEX has determined that the Company is not in compliance with certain conditions of the continued listing standards of Section 1003aii of the AMEX Company Guide. Specifically, AMEX noted that...
Senesco Technologies Reports First Quarter Fiscal 2007 Financial Results
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) reported financial results for the three months ended September 30, 2006. The net loss for the three month period ended September 30, 2006 was $600,465, or $0.04 per share, compared with a net loss of $897,122, or...
Senesco to Present at BIO 2006 Business Forum
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) today announced that the Company will be presenting at BIO 2006 Business Forum, which is part of BIO 2006, the Biotechnology Industry Organization's Annual International Convention being held at McCormick Place Convention Center in Chicago from April 8-12,...
Charles Dinarello, M.D., Member of Senesco's Scientific Advisory Board, to Make Keynote Presentation at Inflammation Conference
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today that Charles Dinarello, M.D., Professor of Medicine at the University of Colorado and member of Senesco's Scientific Advisory Board will make one of three keynote presentations at the upcoming Strategic Research Institute's Inflammation and Immune Diseases...
Senesco Technologies to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare Conference
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX: SNT) today announced that its president and CEO, Bruce Galton, is scheduled to make a formal presentation at the upcoming Rodman & Renshaw Techvest Seventh Annual Healthcare Conference. The presentation is scheduled for 12:20 p.m. Eastern Time on...
Senesco Technologies to Present at the BIO 2005 Business Forum
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) today announced that its president and CEO, Bruce Galton will make a presentation on the company and its research as part of the business forum at the BIO 2005 Annual International Convention. The four-day event will be held...
Senesco Technologies to Present Abstracts at Plant Canada 2005 Conference
NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) today announced that members of its University of Waterloo research staff will present four abstracts at Plant Canada 2005. This conference, the first joint meeting of six major Canadian scientific societies dedicated to plant research, will take place...



